Harris-Love Michael O, Fernandez-Rhodes Lindsay, Joe Galen, Shrader Joseph A, Kokkinis Angela, La Pean Kirschner Alison, Auh Sungyoung, Chen Cheunju, Li Li, Levy Ellen, Davenport Todd E, Di Prospero Nicholas A, Fischbeck Kenneth H
Research Service/Geriatrics and Extended Care, Washington, DC Veterans Affairs Medical Center, 50 Irving Street, NW, Room 11G, Washington, DC 20422, USA ; School of Public Health and Health Services, George Washington University, 2033 K Street, NW, Suite 210, Washington, DC 20006, USA ; Rehabilitation Medicine Department, Clinical Center, Department of Health and Human Services (DHHS), National Institutes of Health (NIH), 10 Center Drive, Bethesda, MD 20892, USA.
National Institute of Neurological Disorders and Stroke (NINDS), Neurogenetics Branch, Department of Health and Human Services (DHHS), National Institutes of Health (NIH), Building 35, Room 2A-1000, 35 Convent Drive, MSC 3705, Bethesda, MD 20892, USA ; Department of Epidemiology, University of North Carolina at Chapel Hill Gillings, School of Global Public Health, 170 Rosenau Hall, Campus Box 7400, 135 Dauer Drive, Chapel Hill, NC 27599, USA.
Rehabil Res Pract. 2014;2014:873872. doi: 10.1155/2014/873872. Epub 2014 May 5.
Purpose. The adult myopathy assessment tool (AMAT) is a performance-based battery comprised of functional and endurance subscales that can be completed in approximately 30 minutes without the use of specialized equipment. The purpose of this study was to determine the construct validity and internal consistency of the AMAT with a sample of adults with spinal and bulbar muscular atrophy (SBMA). Methods. AMAT validity was assessed in 56-male participants with genetically confirmed SBMA (mean age, 53 ± 10 years). The participants completed the AMAT and assessments for disease status, strength, and functional status. Results. Lower AMAT scores were associated with longer disease duration (r = -0.29; P < 0.03) and lower serum androgen levels (r = 0.49-0.59; P < 0.001). The AMAT was significantly correlated with strength and functional status (r = 0.82-0.88; P < 0.001). The domains of the AMAT exhibited good internal consistency (Cronbach's α = 0.77-0.89; P < 0.001). Conclusions. The AMAT is a standardized, performance-based tool that may be used to assess functional limitations and muscle endurance. The AMAT has good internal consistency, and the construct validity of the AMAT is supported by its significant associations with hormonal, strength, and functional characteristics of adults with SBMA. This trial is registered with Clinicaltrials.gov identifier NCT00303446.
目的。成人肌病评估工具（AMAT）是一种基于表现的测试组合，由功能和耐力分量表组成，无需使用专门设备，大约30分钟即可完成。本研究的目的是确定成人脊髓性和延髓性肌萎缩（SBMA）患者样本中AMAT的结构效度和内部一致性。方法。对56名经基因确诊为SBMA的男性参与者（平均年龄53±10岁）进行AMAT效度评估。参与者完成了AMAT以及疾病状态、力量和功能状态的评估。结果。较低的AMAT分数与较长的病程（r = -0.29；P < 0.03）和较低的血清雄激素水平（r = 0.49 - 0.59；P < 0.001）相关。AMAT与力量和功能状态显著相关（r = 0.82 - 0.88；P < 0.001）。AMAT的各个领域表现出良好的内部一致性（Cronbach's α = 0.77 - 0.89；P < 0.001）。结论。AMAT是一种标准化的、基于表现的工具，可用于评估功能受限和肌肉耐力。AMAT具有良好的内部一致性，其与SBMA成人患者的激素、力量和功能特征的显著关联支持了AMAT的结构效度。本试验已在Clinicaltrials.gov注册，标识符为NCT00303446。
